Brief: SAB Biotherapeutics Inc SAB-176 And Oseltamivir Combination Therapy Shows Promising Results In Preclinical Studies
04/05/2023 13:40
May 4 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS INC - SAB-176 AND OSELTAMIVIR
COMBINATION
THERAPY SHOWS PROMISING RESULTS IN PRECLINICAL STUDIES
Source text for Eikon: ID:nGNX5JV7P5
Further company coverage: SABS.O
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies